More about

Ldl Cholesterol

News
March 20, 2023
2 min read
Save

Tailored treat-to-target strategy feasible vs. high-intensity regimen for CAD

Tailored treat-to-target strategy feasible vs. high-intensity regimen for CAD

NEW ORLEANS — Among adults with CAD, a treat-to-target LDL strategy of 50 mg/dL to 70 mg/dL was noninferior to a high-intensity statin therapy for the 3-year composite of death, MI, stroke or coronary revascularization, researchers wrote.

News
March 17, 2023
3 min read
Save

Most patients at high CV risk are not achieving LDL goals

Most patients at high CV risk are not achieving LDL goals

NEW ORLEANS — Most patients at high or very high CV risk do not achieve guideline-recommended LDL goals, according to data from the Family Heart Database presented at the American College of Cardiology Scientific Session.

CME
Video

Navigating the Diagnosis and Treatment of Patients with Narcolepsy and Cardiovascular Risk

Navigating the Diagnosis and Treatment of Patients with Narcolepsy and Cardiovascular Risk
1.50 CME
1.50 ANCC
90 MINS
$0 FEE
CME
Multimedia

Making Sense of LDL-C Combination Therapy in 2022: Strategies and Pearls to Move Beyond Inertia to Improve Patient Outcomes

Making Sense of LDL-C Combination Therapy in 2022: Strategies and Pearls to Move Beyond Inertia to Improve Patient Outcomes
1.25 CME
1.25 ANCC
75 MINS
$0 FEE
News
March 06, 2023
3 min read
Save

Oral PCSK9 inhibitor lowers LDL similar to injection in short-term phase 2 trial

Oral PCSK9 inhibitor lowers LDL similar to injection in short-term phase 2 trial

NEW ORLEANS — In a phase 2 trial, an oral PCSK9 inhibitor lowered LDL about the same amount observed with injectable PCSK9 inhibitors for 8 weeks, researchers reported at the American College of Cardiology Scientific Session.

News
March 05, 2023
3 min read
Save

Causal AI ‘translates’ CAD polygenic risk score into clinically actionable data

Causal AI ‘translates’ CAD polygenic risk score into clinically actionable data

NEW ORLEANS — Causal artificial intelligence used to augment a polygenic risk score for CAD helped estimate how much individual patients must lower their LDL, systolic BP or both to overcome inherited risk for a major coronary event.

CME
Video

What You Need to Know About Optimizing Cardiorenal Outcomes with Novel NonSteroidal MRAs

What You Need to Know About Optimizing Cardiorenal Outcomes with Novel NonSteroidal MRAs
1.50 CME
1.50 ANCC
90 MINS
$0 FEE
CME
Video

Escaping the Current Gaps in the Understanding and Treatment of CKD Anemia: Making Sense of Emerging Therapies

Escaping the Current Gaps in the Understanding and Treatment of CKD Anemia: Making Sense of Emerging Therapies
1.00 CME
1.00 ANCC
60 MINS
$0 FEE
CME
Multimedia

The Disproportionate Burden of Heart Failure in Women: Advances & Expert Perspectives to Improve Diagnosis & Treatment

The Disproportionate Burden of Heart Failure in Women: Advances & Expert Perspectives to Improve Diagnosis & Treatment
1.00 CME
1.00 ANCC
60 MINS
$0 FEE
CME
Video

Assessing the Evolving Role of GLP1-RAs to Reduce Cardiovascular Risk: Emerging Evidence, Evolving Guidance, and Expert Perspectives

Assessing the Evolving Role of GLP1-RAs to Reduce Cardiovascular Risk: Emerging Evidence, Evolving Guidance, and Expert Perspectives
1.00 CME
1.00 ANCC
60 MINS
$0 FEE
View more